Antikor Biopharma

Antikor Biopharma is a private, preclinical-stage biotech leveraging its proprietary OptiLink platform to develop Fragment Drug Conjugates (FDCs), a novel class of antibody-drug conjugates. The company's technology utilizes smaller, stable antibody fragments designed for superior tumour penetration, faster clearance from healthy tissues, and higher drug payloads, potentially leading to a wider therapeutic index in solid tumours. Based in Cambridge, UK, Antikor is actively seeking partnerships to advance its platform and lead candidate, ANT-045, targeting cMET, while presenting its research at major industry conferences.

Proprietary OptiLink platform for generating Fragment Drug Conjugates (FDCs) using small, fully-human antibody fragments engineered for high drug loading, superior tumour penetration, and rapid clearance to improve therapeutic index in solid tumours.

Antikor competes in the next-generation ADC space against companies developing bispecific ADCs, prodrug ADCs, and other novel formats. Its differentiation lies in the small-size, high-DAR fragment approach. It must compete for funding, partnerships, and clinical validation against both large pharma and well-funded biotechs.